We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
240 own
87 watching
Current Price
$54.99
$-0.04
(-0.07%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
4,277.79M
52-Week High
86.95
52-Week Low
42.511
Average Volume
0.32M
Dividend Yield
--
P/E Ratio
16.7148
Market Capitalization4,277.79M
52-Week High86.95
52-Week Low42.511
Average Volume0.32M
Dividend Yield--
P/E Ratio16.7148
What does the Stockal+Disclaimer.pdf do?
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Benzinga
3days ago
Latest Ratings for CRSP DateFirmActionFromTo Feb 2022RBC CapitalMaintainsSector Perform Feb 2022SVB LeerinkMaintainsOutperform Dec 2021Cowen & Co.Initiates Coverage OnMarket Perform View More Analyst Ratings for CRSP View the Latest Analyst Ratings read more...
Benzinga
17days ago
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a market capitalization of $3.91 billion. read more...
Globe Newswire
23days ago
ZUG, Switzerland and BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster on CTX110, its wholly-owned allogeneic CAR-T cell...
Zolmax
1month ago
Bank Julius Baer & Co. Ltd Zurich increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP Get Rating) by 3.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,302 shares of the ...
Globe Newswire
1month ago
ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation and a poster presentation at the Society for Immunotherapy...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$54.99
$-0.04
(-0.07%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00